Described are compounds of the formula (I) which are orally active and bind to aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described are methods of use of the compounds described herein in ameliorating or treating aspartic protease related disorders in a subject in need thereof.
Disclosed are compounds according to Formula I:
wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity.
Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula I.
KENNEWELL, P. D.;MATHARU, S. S.;TAYLOR, J. B.;WESTWOOD, R.;SAMMES, P. G., J. CHEM. SOC. PERKIN TRANS., 1982, N 11, 2563-2570
作者:KENNEWELL, P. D.、MATHARU, S. S.、TAYLOR, J. B.、WESTWOOD, R.、SAMMES, P. G.
DOI:——
日期:——
[EN] RENIN INHIBITORS<br/>[FR] INHIBITEURS DE LA RÉNINE
申请人:VITAE PHARMACEUTICALS INC
公开号:WO2007117482A2
公开(公告)日:2007-10-18
[EN] Disclosed are compounds according to Formula (I): wherein the variables are defined herein. Such compounds are can bind aspartic proteases to inhibit their activity. They are useful in the treatment or amelioration of diseases associated with aspartic protease activity. Also described herein are methods of antagonizing aspartic protease inhibitors in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound according to Formula (I). [FR] L'invention concerne des composés de formule (I), dans laquelle les variables son spécifiées. Lesdits composés peuvent se lier à des protéases aspartiques de manière à inhiber leur activité. Ils sont utilisés dans le traitement ou l'amélioration de maladies associées à l'activité de la protéase aspartique. L'invention concerne également des méthodes de traitement par antagonisme des inhibiteurs de la protéase aspartique chez un sujet nécessitant les soins, comprenant l'administration au sujet d'une quantité efficace de manière thérapeutique d'un composé de formule (I).
Synthesis of γ-aminobutyric acid analogues of restricted conformation. Part 2. The 2-(aminomethyl)cycloalkanecarboxylic acids
作者:Peter D. Kennewell、Saroop S. Matharu、John B. Taylor、Robert Westwood、Peter G. Sammes
DOI:10.1039/p19820002563
日期:——
The syntheses of analogues with restricted rotation about the C(2)–C(3) bond of γ-aminobutyric acid, namely cisand trans-2-(aminomethyl)-cyclopropane and -cyclobutanecarboxylic acids and trans-2-(aminomethyl)cyclohexanecarboxylic acid are described.